BERKELEY, Calif. -- XOMA Ltd. , a leader in the discovery and development of therapeutic antibodies, announced that the Committee for Orphan Medical Products of the European Medicines Agency has adopted a positive opinion and recommends the granting of orphan medicinal product designation for XOMA 052, an antibody to interleukin-1 beta, for the treatment of Behcet's disease.
BERKELEY, Calif. -- XOMA Ltd. , a leader in the discovery and development of therapeutic antibodies, announced receipt of a $750,000 milestone payment under its collaboration with AVEO Pharmaceuticals, Inc. .
BERKELEY, Calif. -- XOMA Ltd. today announced that it has entered into a committed equity financing facility under which it has the option to sell up to $30 million of its registered common shares to Azimuth Opportunity Ltd. over a 12-month period.
According to various reports, biotech giant French pharmaceutical giant Sanofi-Aventis has approached Genzyme as a possible acquisition, sending shares of the latter soaring by 15% in afternoon trading.
BERKELEY, Calif. -- XOMA Ltd. , a leader in the discovery and development of therapeutic antibodies, announced that it has reached the enrollment goal of 325 patients for its Phase 2b dose-ranging clinical trial of XOMA 052, and that it expects patient enrollment to close in the next three weeks, with top-line results available in the first quarter of 2011.
ORLANDO, Fla. -- XOMA Ltd. , a leader in the discovery and development of therapeutic antibodies, will be presenting new preclinical data in an animal model of Type 2 diabetes in which its anti-inflammatory therapeutic antibody candidate, XOMA 052, was used as monotherapy and in combination with the marketed anti-diabetic drugs exendin-4 (Byetta) or sitagliptin (Januvia).
BERKELEY, Calif. -- XOMA Ltd. , a leader in the discovery and development of therapeutic antibodies, announced the publication of data from a mouse model of diet-induced obesity in the June, 2010 edition of the journal Endocrinology.
BERKELEY, Calif., July 29, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that the Committee for Orphan Medical Products of the European Medicines Agency (EMA) has adopted a positive opinion and recommends the granting of orphan medicinal product designation for XOMA 052, an antibody to interleukin-1 beta, for the treatment of Behcet's disease. Positive opinions are submitted to the European Commission for decision and are generally adopted within 30 days of receipt. 2010 07 29 08:16
BERKELEY, Calif., July 26, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced receipt of a $750,000 milestone payment under its collaboration with AVEO Pharmaceuticals, Inc. (Nasdaq:AVEO). The milestone payment resulted from AVEO's recent initiation of a Phase 2 clinical trial to evaluate its AV-299 antibody for the treatment of non-small cell lung cancer. AV-299 is a humanized antibody to hepatocyte growth factor (HGF). 2010 07 26 07:45
BERKELEY, Calif., July 23, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA) today announced that it has entered into a committed equity financing facility under which it has the option to sell up to $30 million of its registered common shares to Azimuth Opportunity Ltd. over a 12-month period. XOMA is not obligated to utilize any of the facility and remains free to enter other financing transactions. 2010 07 26 02:15
XOMA enters into $30 mln committed equity financing facility Co announced that it has entered into a committed equity financing facility under which it has the option to sell up to $30 mln of its 2010 07 23 16:47
Are all of your stock picks winners? Sick and tired of making money hand over fist? Then look no further because I’ve got a couple of ways you can reconnect with the rest of us mere mortals by learning to spot losing propositions. If losing money is not your goal, that’s even more of a reason to read on because even seasoned investors can find themselves being lured into these money traps.
Losing proposition #1: The one-trick pony company Although I’ve railed against this type of investment before, it bears repeating because apparently many people are still being taken in by this...
XOMA has encouraging news today. But recently the firm’s stock plummeted for reasons not related to the firm’s technological capabilities, but to a mixture of inherited consequences of bad financial decisions, past unethical behavior and, in some circumstances, bad luck. Investors’ agitation - well reflected in their exaggerated reactions towards some of the firm’s unfortunate news, has also contributed to the stock’s plummeting. The negative chain reaction began a few years ago when Xoma’s investigational drug for sepsis failed to pass the approval test even though it saved children’s lives in...
In September 2009, Osiris Therapeutics, Inc. (OSIR) reported preliminary results from two Phase III trials evaluating its Prochymal product candidate for the treatment of acute graft-versus-host disease [GVHD]. Unfortunately, neither trial reached its primary endpoint, sending shares from $14 to a 52-week low of $5.35 by November 2009. The results were the latest in a number of late-stage, clinical trial setbacks for the treatment of GVHD [see table 1], prompting us to review this very complicated disease in search of future treatment opportunities.
In response to a number of requests that I've received via email or comments asking for 'VFC's Take' on numerous stocks that readers have found, I'll do my best to address as many as I can, as long as everyone takes a few things into account while reading:
- I have not thoroughly researched all of the stocks that I'm about to comment on. I've done the initial Due Diligence (DD) but my opinions are mostly based on my first impressions of the stock. I'm merely providing VFC's Take, as requested. Use that as a starting point to...
By Jeffrey Martini, PhD., Vice President of MD Becker Partners LLC
Approximately 250 million people worldwide have been diagnosed with diabetes mellitus and that number is growing with the increasing obesity population. Broadly, patients with diabetes are characterized by elevated blood glucose levels that result from either insufficient insulin secretion (type-1 diabetes) or ineffective insulin action (type-2 diabetes). The market for treating patients with diabetes is large and complex and is valued at over $90 billion (Ref 1).
Below are the top 10 Micro Cap stocks (market cap < $300 million) with highest upside potential, based on the difference between current price and Wall Street analysts' average target price. MBT ...
LSI Corporation (NYSE: LSI) plunged by 13.92% and closed at $4.08 with total traded volume of 39.56 million shares. Its price to earnings ratio stood at 34. LSI Corporation (LSI) designs, develops ...
XOMA Ltd. (XOMA) [Chart - Analysis - News] established a new 52-week low yesterday at $0.30. Clearly investors are not enthusiastic about the firm's prospects. The decline was accompanied by ...
BERKELEY, Calif., Jul 29, 2010 (GlobeNewswire via COMTEX) -- XOMA Ltd. (NASDAQ:XOMA) , a leader in the discovery and development of therapeutic antibodies, announced that the Committee for Orphan ...
XOMA Limited (NASDAQ: XOMA) plunged by 5.70% to close at $0.29 whereas overall traded volume stood at 5.51 million shares. XOMA Ltd. (XOMA) is a biopharmaceutical company focused on the discovery ...
(EMAILWIRE.COM, July 29, 2010 ) New York, NY -XOMA Limited (NASDAQ:XOMA) lost 5.70% to $0.296 on 5.52 million shares. XOMA Ltd. is a biopharmaceutical company focused on the discovery, development ...
By Chip Brian XOMA (NASDAQ:XOMA) traded in a range yesterday that spanned from a low of $0.30 to a high of $0.33. Yesterday, the shares fell 3.55%, which took the trading range below the 3-day low ...
(PennystockLive.com, July 28, 2010) San Antonio, TX ?Melco Crown Entertainment Ltd (NASDAQ: MPEL) dropped by 3.28% to close at $4.13 whereas overall traded volume stood at 8.44 million shares ...
XOMA Limited (NASDAQ: XOMA) plunged by 7.65% to close at $0.31 with overall traded volume of 82.03 million. Its total market capitalization stood at $82.03 million. XOMA Ltd. (XOMA) is a ...
Discovery Laboratories, Inc. (NASDAQ: DSCO) closed at $0.24 after moving up by 4.48% whereas overall traded volume stood at 4.51 million shares. Discovery Laboratories, Inc. is a biotechnology ...
Stock News 
